These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 10490729

  • 1. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
    Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R, Miller C, Marcellus D, Abrams R, Hess A.
    Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
    [Abstract] [Full Text] [Related]

  • 2. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J, Johnson E, Goldman N, Devereux L, Grana G, Hageboutros A, Fernandez E, Constantinou C, Harrer W, Viner E, Goldberg J.
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [Abstract] [Full Text] [Related]

  • 3. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [Abstract] [Full Text] [Related]

  • 4. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
    Stein M, Feldman E, Seiter K, Chiao JW, Goff H, Baskind P, Beer M, Ahmed T.
    Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
    [Abstract] [Full Text] [Related]

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G, Beguin Y.
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New conditioning regimens for high risk marrow transplants.
    Jones RJ, Santos GW.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [Abstract] [Full Text] [Related]

  • 14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 15. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF, Gómez-García de Soria V, Pinilla I, Lamana M, Figuera A, Arranz R, Cámara R, Fernández-Villalta MJ, Alegre A, Fernández-Rañada JM.
    Med Clin (Barc); 1997 Feb 15; 108(6):201-6. PubMed ID: 9102484
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L, Carson E, Eisbruch A, Dawson LA, McDonagh K, Ferrara J, Uberti J.
    Bone Marrow Transplant; 2001 Apr 15; 27(8):801-7. PubMed ID: 11477436
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Apr 15; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S.
    Clin Cancer Res; 2002 Apr 15; 8(4):1014-20. PubMed ID: 11948108
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.